News

Sanofi teams up with Google
Enlarge image

DiabetesFrance

Sanofi teams up with Google

01.09.2015 - Sanofi is partnering up with Google’s life sciences team with an ambitious goal: to change the face of diabetes management.

The two companies, each leading in their respective fields, plan to transform type 1 and type 2 diabetes care. They aim to find better ways to collect, analyse and understand multiple sources of information impacting diabetes. Paris-based Sanofi, a longstanding leader in diabetes care, is pairing its expertise with Google’s know-how in analytics, miniturised electronics and low power chip design.

The tools to be developed are meant to bring previously siloed solutions together. They also strive to enable new kinds of interventions, including health indicators such as blood glucose and hemoglobin A1c levels, patient-reported information, medication regimens and sensor devices. The hope is that it will be easier for patients to successfully manage their diabetes, which would reduce the risk of complications, improve outcomes and ultimately lower costs. “With new technologies emerging to provide a more continuous and real-time view of a patient's health, we can see the promise for more proactive and effective ways to control diabetes,” said Andy Conrad, CEO of the life sciences team at Google.

Sanofi CEO Olivier Brandicourt commented: “This initiative combines Sanofi's strength and knowledge in diabetes with Google's leadership in technology and analytics to create a first-of-its-kind initiative with the potential to transform diabetes care.” John L. Brooks, III, President and CEO of the Joslin Diabetes Center, which is a partner to the collaboration, expressed hopes that “technology, sensors, analytics, and digital solutions will revolutionise how blood sugars are managed, which will deliver improved quality of life, lowering the risk of complications and reducing the costs and barriers associated with diabetes care.” Brooks added: “Ultimately, I truly hope we're able to turn the Joslin Diabetes Center into a museum.”


© european-biotechnology-news.com/um

http://www.european-biotechnology-news.com/news/news/2015-04/diabetes-sanofi-teams-up-with-google.html

M&ASwitzerlandFrance

31.08.2015 In order to boost its active cosmetic ingredients business, the Swiss flavour and fragrance giant Givaudan has acquired Volketswil-based Induchem Holding and all its subsidiaries.

BioeconomyEU

26.08.2015 In its second call for proposals, the Bio-Based Industries Joint Undertaking has earmarked €106m for the research and development of useful bio-based products.

OncologyNorway

25.08.2015 Oslo Cancer Cluster is inaugurating its NOK1bn (€107m) Innovation Park. None other than Norwegian prime minister Erna Solberg officially opened the doors to the research park on August 24th.

LicensingUKSwitzerland

21.08.2015 Novartis Pharma AG has secured all remaining rights to antibody hopeful ofatumumab. Seller GlaxoSmithKline is set to receive up to US$1bn (€919m) for the treatment for MS and other autoimmune indications.

LicensingDenmark

18.08.2015 Danish Novo Nordisk is climbing on the antibody therapeutics bandwagon in a US$500m licensing agreement with antibody-specialist Genmab.

M&ASwitzerland

13.08.2015 Roche is stepping up its commitment in the fight against drug resistant “superbugs” with its takeover of US diagnostics play Geneweave, for up to US$425m.

M&AUK

11.08.2015 Biotech bug controllers Oxitec has been bought by US biotech Intrexon Corporation for $160m (€145m). The Oxford University spin-out specialises in environmentally friendly technology to control pests such as mosquitoes, which cause dengue fever and other diseases.

Research and DevelopmentFranceGermany

07.08.2015 In a deal worth more than €300m, Sanofi has partnered up with German drug discovery and development company Evotec in order to develop beta cell-modulating diabetes therapies.

© 2007-2015 BIOCOM

http://www.european-biotechnology-news.com/news/news/pos/1.html?cHash=8305edff5982cb307c5ea48106acb36a&sort=desc

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • EVOLVA (CH)1.49 CHF12.03%
  • TIGENIX (B)1.23 EUR9.82%
  • OREXO (S)49.10 SEK8.39%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)11.35 SEK-11.67%
  • BIOTIE THERAPEUTICS (FI)0.20 EUR-9.09%
  • PROTHENA PLC (IE)52.70 USD-6.54%

TOP

  • KARO BIO (S)41.90 SEK2568.8%
  • BIOTECH PHARMACON (N)16.80 NOK80.6%
  • TRANSGENE (F)4.86 EUR75.5%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-50.0%
  • NEUROVIVE PHARMACEUTICAL AB (S)11.35 SEK-49.6%
  • THROMBOGENICS (B)2.85 EUR-42.1%

TOP

  • KARO BIO (S)41.90 SEK4661.4%
  • ADOCIA (F)89.30 EUR409.1%
  • GALAPAGOS (B)53.25 EUR325.3%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-87.5%
  • NEUROVIVE PHARMACEUTICAL AB (S)11.35 SEK-81.7%
  • BIOTEST (D)20.30 EUR-76.5%

No liability assumed, Date: 03.09.2015